Articles tagged "Renal function"

2018 American Transplant Congress
Allograft Function after 12 Months with Everolimus Plus Either Tacrolimus or Cyclosporine Compared to a Standard Regimen of Tacrolimus with MPA in De Novo Renal Transplant Recipients: The ATHENA Study
B. Nashan,¹ C. Sommerer,¹ B. Suwelack,¹ D. Dragun,¹ O. Witzke,¹ C. Hugo,¹ N. Kamar,² P. Merville,² A. Hauser,¹ P. Schenker,¹ M. Junge,³ F. Thaiss.¹
¹Athena Study Group, Germany; ²Athena Study Group, France; ³Novartis, Pharma, Germany.
The ATHENA study was designed to compare efficacy, safety and outcomes on renal function [GFR] of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A…
2018 American Transplant Congress
Long-Term Renal Function in Living Kidney Donors with Renal Cysts
M. Waldram, A. Thomas, A. Muzaale, C. Holscher, A. Nguyen, S. Halpern, S. Anjum, J. Alejo, B. Boyarsky, S. Ottman, J. Garonzik-Wang, D. Segev, A. Massie.
JHU, Baltimore.
Renal cysts found during the evaluation of living kidney donor (LKD) candidates are often regarded as benign. However, it is possible that these structural abnormalities…
2018 American Transplant Congress
Liver Transplantation with or without Left Renal Vein Ligation: Comparative Study of 105 Cases
M. Perosa,¹ H. Noujaim,¹ J. Branez,¹ L. Mota,¹ B. Zeballos,¹ R. Santos,¹ A. Watanabe,² G. Ferreira,² A. Moraes,² A. Silvestre,³ G. Martinho,⁴ N. Siqueira,⁵ T. Genzini.¹
¹Abdominal Organ Transplantation, Leforte Hospital, Sao Paulo, Brazil; ²ICDF Hospital, Brasilia, Brazil; ³Medical School, Sao Camilo, Sao Paulo, Brazil; ⁴Medical School, Santa Casa, Sao Paulo, Brazil; ⁵Hospital das Clínicas, Rio Branco, Acre, Brazil.
The presence of large spontaneous splenorenal shunts (SSRS) is a risk factor for low portal flow and graft dysfunction after liver transplantation (LT). Left renal…
2018 American Transplant Congress
Ischemia Reperfusion Injury in Liver Transplantation is Associated with Acute Kidney Injury: Role of Inflammatory Mediators
P. Mihaylov,^1,2 P. Li,¹ J. Skill,¹ L. Timsina,¹ J. Fridell,¹ B. Ekser,¹ R. Mangus,¹ C. Kubal.¹
¹Surgery, Indiana University, Indianapolis; ²Surgery, University of Pavia, Pavia, Italy.
Background: The impact of liver allograft ischemia/reperfusion injury (IRI) on native renal function remains to be characterized. We hypothesized that elevated levels of circulating inflammatory…
2018 American Transplant Congress
Delayed Recovery of Renal Function after Donor Nephrectomy
J. Na,¹ J. Park,¹ M-.G. Yoon,¹ H. Lee,² Y. Yoon,³ K. Huh,⁴ M. Kim,⁴ S. Kim,⁴ Y. Kim,⁴ W. Han.¹
¹Department of Urology, Yonsei University College of Medicine, Urological Science Institute, Seoul, Korea; ²Department of Urology, National Health Insurance Service Ilsan Hospital, Goyang-si, Korea; ³Department of Urology, Hanyang University Medical Center, Seoul, Korea; ⁴Department of Surgery-Transplantation, Yonsei University College of Medicine, Seoul, Korea.
Introduction:Among living kidney donors at risk of CKD at 1 year after nephrectomy, some donors remain with poor renal function while many show delayed recovery…
2018 American Transplant Congress
Outcomes in Liver Transplant Patients on Renal Sparing Protocol
A. Polyak,¹ D. Ganger,² A. Shetty.²
¹New York Medical College, Valhalla, NY; ²Comprehensive Transplant Center, Northwestern University, Chicago, IL.
As liver transplant outcomes have improved, long term native kidney function has taken a critical role in patient survival. Calcineurin inhibitors (CNIs), such as Tacrolimus…
2018 American Transplant Congress
Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection – A Double-Blind Randomized Placebo-Controlled Trial (BORTEJECT Study)
F. Eskandary,¹ H. Regele,² G. Bond,¹ N. Kozakowski,² M. Wahrmann,¹ L. Hidalgo,³ H. Haslacher,⁴ C. Kaltenecker,¹ M-.B. Aretin,⁵ R. Oberbauer,¹ J. Reeve,⁶ P. Halloran,⁶ G. Böhmig.¹
¹Nephrology and Dialysis, Medical University Vienna, Viena, Austria; ²Institute of Clinical Pathology, Medical University Vienna, Vienna, Austria; ³Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ⁴Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria; ⁵Pharmacy Department, General Hospital Vienna, AKH, Vienna, Austria; ⁶Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada.
Background. Antibody-mediated rejection (ABMR) is a leading cause of long-term kidney transplant loss. Optimal treatment of late ABMR is unclear, and our current knowledge is…
2018 American Transplant Congress
Once-Daily MeltDose Tacrolimus Formulation and Renal Function in Caucasian Fast Tacrolimus Metabolizers: Does Early Identification Have an Impact in PK Sensitive Patients?
K. Budde,⁶ B. Suwelack,¹ D. Stevens,³ W. Du,⁴ C. Procaccianti,⁵ C. Maas,⁵ S. Bunnapradist.²
¹University Hospital of Münster, Münster, Germany; ²David Geffen School of Medicine at UCLA, Los Angeles; ³Veloxis Pharmaceuticals, Cary; ⁴Clinical Statistics Consulting, Norrystown; ⁵Chiesi Farmaceutici S.p.A., Parma, Italy; ⁶Charité Universitatsmedizin, Berlin, Germany.
Tacrolimus (TAC) nephrotoxicity can be seen even at low blood trough levels, with factors beyond trough levels potentially contributing. TAC fast metabolizers have higher Cmax,…
2018 American Transplant Congress
Renal and Bone Safety in Post Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis
E. Gane,¹ B. George,¹ S. Munn,¹ H. Wang,² V. Suri,² A. Gaggar.²
¹Auckland City Hospital, Auckland, New Zealand; ²Gilead Sciences, Foster City, CA.
Background and Aims: Chronic Hepatitis B (CHB) remains a leading indication for orthotopic liver transplantation (OLT) globally. Common complications following OLT include renal dysfunction secondary…
2017 American Transplant Congress
Influence of Donor-Specific Antibodies on Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.
J. Cruzado,¹ H. Holdaas,¹ P. Lopez,² P. Bernhardt,² G. Bader,² F. Claas,¹ W. Arns,¹ M. van der Giet,¹ J. de Fijter.¹
¹ELEVATE Study Group, Llobregat Catalunya, Spain; ²Novartis Pharma AG, Basel, Switzerland
Purpose: The development of donor-specific antibody (DSA) is a known risk factor for poor graft outcomes after kidney transplantation (KTx). Previous analysis of the ELEVATE…